Accelerate Diagnostics, Inc. (NASDAQ:AXDX) CEO Jack Phillips Sells 26,545 Shares

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) CEO Jack Phillips sold 26,545 shares of Accelerate Diagnostics stock in a transaction on Friday, April 12th. The stock was sold at an average price of $0.86, for a total transaction of $22,828.70. Following the completion of the transaction, the chief executive officer now directly owns 129,726 shares in the company, valued at $111,564.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Jack Phillips also recently made the following trade(s):

• On Thursday, April 4th, Jack Phillips sold 15,887 shares of Accelerate Diagnostics stock. The stock was sold at an average price of $0.88, for a total transaction of $13,980.56.
• On Thursday, February 1st, Jack Phillips sold 494 shares of Accelerate Diagnostics stock. The stock was sold at an average price of $1.30, for a total transaction of $642.20.

Accelerate Diagnostics Price Performance

NASDAQ:AXDX traded down $0.08 during mid-day trading on Wednesday, hitting $0.74. The company’s stock had a trading volume of 115,691 shares, compared to its average volume of 120,337. Accelerate Diagnostics, Inc. has a 1 year low of $0.73 and a 1 year high of $11.90. The stock has a market cap of $16.01 million, a price-to-earnings ratio of -0.15 and a beta of 0.52. The business’s fifty day moving average is $1.02 and its two-hundred day moving average is $3.23.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Sonora Investment Management Group LLC purchased a new stake in shares of Accelerate Diagnostics during the 3rd quarter worth about $63,000. Swiss National Bank lifted its stake in Accelerate Diagnostics by 19.0% in the 1st quarter. Swiss National Bank now owns 85,300 shares of the medical research company’s stock worth $123,000 after purchasing an additional 13,600 shares in the last quarter. Tejara Capital Ltd purchased a new position in Accelerate Diagnostics in the 3rd quarter worth approximately $78,000. Virtu Financial LLC lifted its stake in Accelerate Diagnostics by 95.4% in the 4th quarter. Virtu Financial LLC now owns 35,771 shares of the medical research company’s stock worth $25,000 after purchasing an additional 17,461 shares in the last quarter. Finally, Bank of Montreal Can purchased a new position in Accelerate Diagnostics in the 1st quarter worth approximately $27,000. Institutional investors and hedge funds own 17.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on AXDX. Craig Hallum cut their price target on shares of Accelerate Diagnostics from $2.00 to $1.00 and set a “hold” rating on the stock in a report on Monday, April 1st. StockNews.com started coverage on shares of Accelerate Diagnostics in a report on Friday, April 12th. They set a “hold” rating on the stock. Finally, William Blair reissued an “outperform” rating on shares of Accelerate Diagnostics in a report on Tuesday, April 2nd.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.